Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum] Pages 4085-4086 | Received 03 Oct 2024, Accepted 03 Oct 2024, Published online: 02 Dec 2024 Cite this arti...
[14]. Injection of CGRP into the facial skin has been found to cause dose-dependent periorbital allodynia, which could be prevented by administration of the CGRP receptor antagonist olcegepant or a monoclonal antibody against CGRP [15]. In rats, injection of CGRP into the facial skin did ...